Fluoxetine tenth anniversary update: The progress continues

Clinical Therapeutics

Volumn 19, Issue 5, 1997, Pages 1135-1250

  Stokes, Peter E ^a   Holtz, Aliza ^b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b Beth Abraham Family of Health Services   (United States)

Author keywords

Aggression; Antidepressants; Anxiety; Augmentation; Children and adolescents; Cytochrome P 450; Depression; Depression subtypes; Dose titration; Eating disorders; Elderly; Fluoxetine; Maintenance therapy; Obsessive compulsive disorder; Overdose; Pharmacoeconomics; Pregnancy; Selective serotonin reuptake inhibitors; Sexual dysfunction; Suicide; Withdrawal

Indexed keywords

ANALGESIC AGENT; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTITUSSIVE AGENT; ANXIOLYTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 ISOENZYME; FLUOXETINE; FLUVOXAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; LITHIUM; METHYLXANTHINE DERIVATIVE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; PINDOLOL; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

AGGRESSION; ALCOHOLISM; ANGER; ANOREXIA NERVOSA; CLINICAL TRIAL; DEPRESSION; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DYSTHYMIA; ENZYME INDUCTION; FEEDING DISORDER; GENETIC VARIABILITY; HUMAN; LACTATION; OBSESSION; PREMATURE EJACULATION; REVIEW; SEXUAL DYSFUNCTION; TERATOGENICITY; WITHDRAWAL SYNDROME;

EID: 0030722053     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80066-5     Document Type: Article

References (453)

1. Richelson E. Treatment of acute depression. Psychiatr Clin North Am. 1993; 16:461-478.
2. Thase ME, Kupfer DJ. Recent developments in the pharmacotherapy of mood disorders. J Consult Clin Psychol. 1996; 64:646-659.
3. Katon W, Von Korff M, Lin E, et al. Adequacy and duration of antidepressant treatment in primary care. Med Care. 1992;30:67-76.
4. Wells KB, Katon W, Rogers B, Camp P. Use of minor tranquilizers and antidepressant medications by depressed outpatients: Results from the medical outcomes study. Am J Psychiatry. 1994;151:694-700.
5. Preskorn SH. Antidepressant drug selection: Criteria and options. J Clin Psychiatry. 1994;55(Suppl A):6-22.
6. Wong DT, Bymaster FP, Engleman EA. Minireview: Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication. Life Sci. 1995;57:411-441.
7. Guze BH, Gitlin M. New antidepressants and the treatment of depression. J Fam Pract. 1994;38:49-57.
8. Psychopharmacologic drugs. In: Drugs Used in Mood Disorders. Drug Evaluations Subscription. Chicago, III: American Medical Association; 1992;1:32.
9. Beasley CM Jr, Sayler ME, Cunningham GE, et al. Fluoxetine in tricyclic refractory major depressive disorder. J Affect Disord. 1990;20:193-200.
10. Lader M. Fluoxetine efficacy vs comparative drugs: An overview. Br J Psychiatry. 1988;153(Suppl 3):51-58.
11. Montgomery SA, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry. 1988;153(Suppl 3):69-76.
12. Reimherr FW, Wood DR, Byerley B, et al. Characteristics of responders to fluoxetine. Psychopharmacol Bull. 1984;20: 70-72.
13. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry. 1988;45:129-137.
14. Donoghue JM. A comparison of prescribing patterns of selective serotonin reuptake inhibitors in the treatment of depression in primary care in the United Kingdom. J Serotonin Res. 1995;1:47-51.
15. Stokes PE. Fluoxetine: A five-year review. Clin Ther. 1993;15:216-243.
16. Asberg M, Träskman L, Thorén P. 5-HIAA in cerebrospinal fluid - a biochemical suicide predictor? Arch Gen Psychiatry. 1976;33:1193-1197.
17. Leonard BE. SSRI differentiation: Pharmacology and pharmacokinetics. Hum Psychopharmacol. 1995;10:S149-S158.
18. Prozac® (fluoxetine hydrochloride) Product Information. Dista Products Company, a division of Eli Lilly Industries, Inc, Carolina, Puerto Rico, a subdivision of Eli Lilly and Company, Indianapolis, Indiana. May 17, 1995.
19. Cohen LJ, DeVane CL. Clinical implications of antidepressant pharmacokinetics and pharmacogenetics. Ann Pharmacother. 1996;3:1471-1480.
20. Menys VC, Smith CCT, Lewins P, et al. Platelet 5-hydroxytryptamine is decreased in a preliminary group of depressed patients receiving the 5-hydroxytryptamine re-uptake inhibiting drug fluoxetine. Clin Sci. 1996;91:87-92.
21. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996;31:444-469.
22. Catterson ML, Preskorn SH. Pharmacokinetics of selective serotonin reuptake inhibitors: Clinical relevance. Pharmacol Toxicol. 1996;78:203-208.
23. Ereshefsky L, Riesenman C, Lam YWF. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. Clin Pharmacokinet. 1995;29(Suppl 1):10-19.
24. Preskorn SH, Magnus RD. Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: In vitro and in vivo findings and their implications for patient care. Psychopharmacol Bull. 1994; 30:251-259.
25. Rasmussen BB, Nielsen KK, Brosen K. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Psychopharmacology (Berl). 1994;114(3):B9. Abstract.
26. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153:311-320.
27. Riesenman C. Antidepressant drug interactions and the cytochrome P450 system: A critical appraisal. Pharmacotherapy. 1995;15(6 Pt 2):84S-99S.
28. Krishnan DR, Steffens DC, Doraiswamy PM. Drug interactions. Prim Psychiatry. 1996;January:23-26, 35-45.
29. Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol. 1995;15:387-398.
30. von Moltke LL, Greenblatt DJ, Schmider J, et al. Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. Clin Pharmacokinet. 1995;29(Suppl 1):33-44.
31. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol. 1992;34: 262-265.
32. Otton SV, Wu D, Joffe RT, et al. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther. 1993; 53:401-409.
33. Glue P, Banfield C. Psychiatry, psychopharmacology and P-450s. Hum Psychopharmacol. 1996;11:97-114.
34. Taylor D, Lader M. Cytochromes and psychotropic drug interactions. Br J Psychiatry. 1996;168:529-532.
35. Park BK, Pirmohamed M, Kitteringham NR. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther. 1995;68: 385-424.
36. Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther. 1992;51: 239-248.
37. von Moltke LL. Greenblatt DJ, Duan SX, et al. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: Relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol. 1996;16:104-112.
38. Ereshefsky L, Riesenman C, Lam YWF. Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system. J Clin Psychiatry. 1996;57(Suppl 8):17-25.
39. Marinac JS, Foxworth JW, Willsie SK. Dextromethorphan polymorphic hepatic oxidation in healthy black American adult subjects. Ther Drug Monit. 1995;17: 120-124.
40. DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry. 1994;55(12, Suppl):38-45.
41. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet. 1995;29:192-209.
42. Katz MM, Bowden C, Stokes P, et al. Can the effects of antidepressants be observed in the first two weeks of treatment? Neuropsychopharmacology. 1997;17(2):110-112. Letter.
43. Katz MM, Koslow SH, Maas JW, et al. The timing, specificity and clinical prediction of tricyclic drug effects in depression. Psychol Med. 1987;17:297-309.
44. Holman SL, Tollefson GD. Onset of action in depressed patients treated with fluoxetine or placebo. Neuropsychopharmacology. 1994;10(Suppl 3, Pt 2):162S. Abstract.
45. Bel N, Artigas F. Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nucle: An in vivo microdialysis study. Eur J Pharmacol. 1992;229:101-103.
46. de Montigny C, Aghajanian GK. Tricyclic antidepressants: Long-term treatment increases responsivity of rat forebrain neurons to serotonin. Science. 1978;202: 1303-1306.
47. Chaput Y, Blier P, de Montigny C. Acute and long-term effects of antidepressant serotonin (5-HT) reuptake blockers on the efficacy of 5-HT neurotransmission: Electrophysiological studies in the rat central nervous system. Adv Biol Psychiatr. 1988;17:1-7.
48. 1A receptors in rat brain following antidepressant drug treatment. Synapse. 1989;4:347-352.
49. Moret C, Briley M. Serotonin autoreceptor subsensitivity and antidepressant activity. Eur J Pharmacol. 1990;180: 351-356.
50. Nielsen BM, Behnke K, Arup P, et al. A comparison of fluoxetine and imipramine in the treatment of outpatients with major depressive disorder. Acta Psychiatr Scand. 1993;87:269-272.
51. Workman EA, Short DD. Atypical antidepressants versus imipramine in the treatment of major depression: A meta-analysis. J Clin Psychiatry. 1993;54:5-12.
52. Bowden CL, Schatzberg AF, Rosenbaum A, et al. Fluoxetine and desipramine in major depressive disorder. J Clin Psychopharmacol. 1993;13:305-311.
53. Remick RA, Claman J, Reesal R, et al. Comparison of fluoxetine and desipramine in depressed outpatients. Curr Ther Res. 1993;53:457-465.
54. Fabre LF, Scharf MB, Itil TM. Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression: A clinical study. J Clin Psychiatry. 1991;52(Suppl):62-67.
55. Beasley CM, Sayler ME, Potvin JH. Fluoxetine versus amitriptyline in the treatment of major depression: A multicenter trial, Int Clin Psychopharmacol 1993;8: 143-149.
56. Judd FK, Moore K, Norman TR, et al. A multicentre double-blind trial of fluoxetine versus amitriptyline in the treatment of depressive illness. Aust New Zealand J Psychiatry. 1993;27:49-55.
57. Feighner JP, Cohn JB. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatry. 1985;46: 20-25.
58. Robertson MM, Abou-Saleh MT, Harrison DA, et al. A double-blind, controlled comparison of fluoxetine and lofepramine in major depressive illness. J Psychopharmacol. 1994;8:98-103.
59. Souetre E, Martin P, Lozet H, Monteban H. Quality of life in depressed patients: Comparison of fluoxetine and major tricyclic antidepressants. Int Clin Psychopharmacol. 1996;11:45-52.
60. De Wilde J, Spiers R, Mertens C, et al. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand. 1993;87:141-145.
61. Tignol J. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol. 1993;13(Suppl 2):18S-22S.
62. Gagiano CA. A double-blind comparison of paroxetine and fluoxetine in patients with major depression. Br J Clin Res. 1993; 4:145-152.
63. Aguglia E, Casacchia M, Cassano GB, et al. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression, Int Clin Psychopharmacol. 1993;8:197-202.
64. van Moffaert M, Bartholome F, Cosyns P, et al. A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression. Hum Psychopharmacol. 1995;10:393-405.
65. Bennie EH, Mullin JM, Martindale JJ. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry. 1995;56:229-237.
66. Rapaport M, Coccaro E, Sheline Y, et al. A comparison of fluvoxamine and fluox-etine in the treatment of major depression. J Clin Psychopharmacol. 1996;16: 373-378.
67. Patris M, Bouchard J-M, Bougereol T, et al. Citalopram versus fluoxetine: A double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol. 1996;11:129-136.
68. Gregor KJ, Overhage JM, Coons SJ, McDonald RC. Selective serotonin reuptake inhibitor dose titration in the naturalistic setting, Clin Ther. 1994;16(2):306-315.
69. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: A meta-analysis. BMJ. 1995;310:1433-1438.
70. Montgomery SA, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: Meta-analysis of discontinuation rates, Int Clin Psychopharmacol. 1994;9: 47-53.
71. Montgomery SA, Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis. Int Clin Psychopharmacol. 1995;9(Suppl 4):33-40.
72. Danjou P. A randomized, double-blind comparison of venlafaxine and fluoxetine in inpatients with major depression and melancholia. Neuropsychopharmacology. 1994;10:222S. Abstract.
73. Clerc GE, Ruimy P, Verdeau-Pailles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia, Int Clin Psychopharmacol. 1994;9:138-143.
74. Dierick M, Ravizza L, Realini R, Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry. 1996; 20:57-71.
75. Tylee A, Bowden M, Reynolds A. A comparison of venlafaxine 37.5 mg twice a day with fluoxetine 20 mg once a day in depressed patients treated in general practice. Psychopharmacol Bull. 1996;32:528. Abstract.
76. Ellingrod VL, Perry PJ. Venlafaxine: A heterocyclic antidepressant. Am J Hosp Pharm. 1994;51:3033-3046.
77. Mendels J, Reimherr F, Marcus RN, et al. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. J Clin Psychiatry. 1995;56(Suppl 6):30-36.
78. Rioux R, Kibleur Y, Frachon O, et al. A double-blind comparison of nefazodone and fluoxetine in depressed patients. Psychopharmacol Bull. 1996;32:505. Abstract.
79. Williams R, Edwards RA, Newburn GM, et al. A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders. Int Clin Psychopharmacol. 1993;7:155-158.
80. Lonnqvist J, Sintone H, Syvalahti E, et al. Antidepressant efficacy and quality of life in depression: A double-blind study with moclobemide and fluoxetine. Acta Psychiatr Scand. 1994;89:363-369.
81. Geerts S, Bruynooghe F, De Cuyper H, et al. Moclobemide versus fluoxetine for major depressive episodes. Clin Neuropharmacol. 1994;17(Suppl 1):S50-S57.
82. de Kock RF, Ashley-Smith A, Schall R. A double-blind, multicentre study with moclobemide and fluoxetine in treatment of major depressive episode. Neuropsychopharmacology. 1994;10:61S. Abstract.
83. Gattaz WF, Kick H, Vogel P. Moclobemide vs fluoxetine in the treatment of major depression. Neuropsychopharmacology. 1994;10:62S. Abstract.
84. Reynaert C, Parent M, Mirel J, et al. Moclobemide versus fluoxetine for a major depressive episode. Psychopharmacology. 1995;118:183-187.
85. Lonnqvist J, Sihvo S, Syvalahti E, et al. Moclobemide and fluoxetine in the prevention of relapses following acute treatment of depression. Acta Psychiatr Scand. 1995;91:189-194.
86. Donoghue JM. A comparison of prescribing patterns of selective serotonin reuptake inhibitors in the treatment of depression in primary care in the United Kingdom. J Serotonin Res. 1996;1:47-51.
87. Montgomery SA. The efficacy of fluoxetine as an antidepressant in the short and long term. Int Clin Psychopharmacol. 1989;4(Suppl 1):113-119.
88. Pande AC, Sayler ME. Severity of depression and response to fluoxetine. Int Clin Psychopharmacol. 1993;8:243-245.
89. Levine S, Deo R, Mahadevan K. A comparative trial of a new antidepressant, fluoxetine. Br J Psychiatry. 1987;150: 653-655.
90. Martensson B, Nyberg S, Toresson G, et al. Fluoxetine treatment of depression. Clinical effects, drug concentrations, and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid. Acta Psychiatr Scand. 1989;79: 586-596.
91. Hale AS, Stokes PE. The utility of serotonin reuptake inhibitors in endogenous and severe depression. In: Freeman HL, ed. The Uses of Fluoxetine in Clinical Practice. Royal Society of Medicine Services International Congress and Symposium Series No. 183. London, England: Royal Society of Medicine Services; 1991:15-25.
92. Evans ME, Lye M. Depression in the elderly physically ill: An open study of treatment with the 5-HT reuptake inhibitor fluoxetine. J Clin Exp Gerontol. 1992;14: 297-307.
93. Roose SP, Glassman AH, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry. 1994;151:1735-1739.
94. Dunlop SR, Dornseif BE, Wernicke JF, Potvin JH. Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacol Bull. 1990; 26:173-180.
95. Orengo CA, Kunik ME, Molinari V, Workman RH. The use and tolerability of fluoxetine in geropsychiatric inpatients. J Clin Psychiatry. 1996;57:12-16.
96. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: Results from the Medical Outcomes Study. JAMA. 1989;262: 914-919.
97. Ravindran AV, Bialik RJ, Lapierre YD. Therapeutic efficacy of specific serotonin reuptake inhibitors (SSRIs) in dysthymia. Can J Psychiatry. 1994;39:21-26.
98. Hellerstein DJ, Yanowitch P, Rosenthal J, et al. A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. Am J Psychiatry. 1993;150:1169-1175.
99. Rosenthal J, Hemlock C, Hellerstein DJ, et al. A preliminary study of serotonergic antidepressants in treatment of dysthymia. Prog Neuropsychopharmacol Biol Psychiatry. 1992;16:933-994.
100. Hellerstein DJ, Samstag LW, Cantillon M, et al. Follow-up assessment of medication-treated dysthymia. Prog Neuropsychopharmacol Biol Psychiatry. 1996;20:427-442.
101. Hellerstein DJ, Yanowitch P, Rosenthal J, et al. Long-term treatment of double depression: A preliminary study with serotonergic antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18:139-147.
102. Duarte A, Mikkelsen H, Delini-Stula A. Moclobemide versus fluoxetine for double depression: A randomized doubleblind study, J Psychiatr Res. 1996;30: 453-458.
103. Johnson J, Weissman MM, Klerman GL. Service utilization and social morbidity associated with depressive symptoms in the community. JAMA. 1992;267: 1478-1483.
104. Broadhead WE, Blazer DG, George LK, Tse CK. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA. 1990;264: 2524-2528.
105. Hamilton M. Distinguishing between anxiety and depressive disorders. In: Last CA, Hersen M, eds. Handbook of Anxiety Disorders. Oxford: Pergamon Press; 1988:143-155.
106. Liebowitz MR. Depression with anxiety and atypical depression. J Clin Psychiatry. 1993;54(Suppl):10-14.
107. Schatzberg AF. Fluoxetine in the treatment of comorbid anxiety and depression. J Clin Psychiatry Monogr. 1995; 3:2-12.
108. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
109. Feighner JP. A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder. J Clin Psychiatry. 1985;45:369-372.
110. Tollefson GD, Souetre E, Thomander L, et al. Comorbid anxious signs and symptoms in major depression: Impact on functional work capacity and comparative treatment outcomes. Int Clin Psychopharmacol. 1993;8:281-293.
111. Beasley CM Jr, Sayler ME, Bosomworth JC, Wernicke JF. High dose fluoxetine: Efficacy and activating-sedating effects in agitated and retarded depression. J Clin Psychopharmacol. 1991;11:166-174.
112. Tollefson GD, Holman SL, Sayler ME, Potvin JH. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features. J Clin Psychiatry. 1994;55:50-59.
113. Moskowitz H, Burns M. The effects on performance of two antidepressants, alone and in combination with diazepam. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:783-792.
114. Filteau MJ, Baruch P, Lapierre YD, et al. SSRIs in anxious-agitated depression: A post-hoc analysis of 279 patients. Int Clin Psychopharmacol. 1995;10:51-54.
115. Sheehan DV, Harnett-Sheehan K. The role of SSRIs in panic disorder. J Clin Psychiatry. 1996;57(Suppl 10):51-58.
116. den Boer JA, Westenberg HGM. Serotonergic compounds in panic disorder, obsessive-compulsive disorder and anxious depression: A concise review. Hum Psychopharmacol. 1995;10:S173-S183.
117. Gorman JM, Leibowitz MR, Fyer AJ, et al. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol. 1987;7:329-332.
118. Schneier F, Liebowitz MR, Davies SO, et al. Fluoxetine in panic disorder. J Clin Psychopharmacol. 1990;10:119-121.
119. Louie AK, Lewis TB, Lannon RA. Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry. 1993;54:435-438.
120. Emmanuel NP, Cosby C, Ware M, Lydiard RB. The efficacy of once a week fluoxetine dosing in the treatment of panic disorder. Psychopharmacol Bull. 1996; 32:438. Abstract.
121. Satterlee WG, Faries D. The effects of fluoxetine on symptoms of insomnia in depressed patients. Psychopharmacol Bull. 1995;31:227-237.
122. Tollefson GD, Holman SL. Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebocontrolled trial of fluoxetine in geriatric major depression. Int Clin Psychopharmacol. 1993;8:253-259.
123. Schatzberg AF, Dupont RL, Siegal A. SSRI treatment controversies: The elderly. J Clin Psychiatry Intercom. 1996; July: 1-11.
124. NIH Consensus Development Panel on Depression in Late Life. Diagnosis and treatment of depression in late life. JAMA. 1992;268(8):1018-1024.
125. Tollefson GD, Bosomworth JC, Heiligenstein JH, and the Fluoxetine Study Group. A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. Int Psychogeriatr. 1995;7:89-104.
126. Koran LM, Hamilton SH, Hertzman M, et al. Predicting response to fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol. 1995;15: 421-427.
127. Small GW, Hamilton SH, Bystritsky A, and the Fluoxetine Collaborative Study Group. Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Int Psychogeriatr. 1995;7(Suppl):41-53.
128. McWilliam C, Dover S. A naturalistic study into the use of fluoxetine in elderly depressive patients. Neuropsychopharmacology. 1994;10:101S. Abstract.
129. Heiligenstein JH, Ware JE, Beusterien KM, et al. Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression. Int Psychogeriatr. 1995;7(Suppl):125-137.
130. Schone W, Ludwig M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol. 1993;13(Suppl 2):34S-39S.
131. Geretsegger C, Bohmer F, Ludwig M. Paroxetine in the elderly depressed patient: Randomized comparison with fluoxetine of efficacy, cognitive and behavioral effects. Int Clin Psychopharmacol. 1994;9:25-29.
132. La Pia S, Giorgio R, Ciriello R, et al. Evaluation of the efficacy, tolerability, and therapeutic profile of fluoxetine versus mianserin in the treatment of depressive disorders in the elderly. Curr Ther Res. 1992;52:847-858.
133. La Pia S, Giorgio D, Ciriello R, et al. Double blind controlled study to evaluate the effectiveness and tolerability of fluoxetine versus mianserin in the treatment of depressive disorders among the elderly and their effects on cognitivebehavioral parameters. New Trends Exp Clin Psychiatry. 1992;8:139-146.
134. Nobler MS, Devanand DP, Kim MK, et al. Fluoxetine treatment of dysthymia in the elderly. J Clin Psychiatry. 1996;57: 254-256.
135. Fairweather DB, Kerr JS, Harrison DA, et al. A double blind comparison of the effects of fluoxetine and amitriptyline on cognitive function in elderly depressed patients. Hum Psychopharmacol. 1993;8: 41-47.
136. Alderman CP. A retrospective review of fluoxetine use in an acute care geriatric hospital. Aust J Hosp Pharm. 1993;23: 116-120.
137. Mesters P, Cosyns P, Dejaiffe G, et al. Assessment of quality of life in the treatment of major depressive disorder with fluoxetine, 20 mg, in ambulatory patients aged over 60 years. Int Clin Psychopharmacol. 1993;8:337-340.
138. Gregoire J, de Leval N, Mesters P, Czarka M. Validation of the Quality of Life in Depression scale in a population of adult depressive patients aged 60 and above. Q Life Res. 1994;3:13-19.
139. Devanand DP, Kim MK, Nobler MS. Fluoxetine discontinuation in elderly dysthymic patients. Am J Geriatr Psychiatry. 1997;5:83-87.
140. Salzman C. Pharmacologic treatment of depression in the elderly. J Clin Psychiatry. 1993;54(Suppl 2):23-28.
141. Harris MG, Benfield P. Fluoxetine. Drugs Aging. 1995;6:64-84.
142. Brymer C, Winograd CH. Fluoxetine in elderly patients: Is there cause for concern? J Am Geriatr Soc. 1992;40: 912-915.
143. Sharma H, Pompei P. Antidepressantinduced hyponatraemia in the aged. Avoidance and management strategies. Drugs Aging. 1996;8:430-435.
144. Greden JF. Antidepressant maintenance medications: When to discontinue and how to stop. J Clin Psychiatry. 1993; 54(Suppl):39-45.
145. Blomgren SL, Fava M, Ascroft RC, et al. Risk of adverse events and depressive symptom breakthrough following brief interruptive selective serotonin reuptake inhibitor therapy in a randomized clinical trial. Submitted for publication.
146. Tollefson GD, Greist JH, Jefferson JW, et al. Is baseline agitation a relative contraindication for a selective serotonin re-uptake inhibitor? A comparative trial of fluoxetine versus imipramine. J Clin Psychopharmacol. 1994;14:385-391.
147. Spiker DG, Weiss JC, Dealy RS, et al. The pharmacological treatment of delusional depression. Am J Psychiatry. 1985; 142:430-436.
148. Narayan M, Meckler L, Nelson JC. Fluoxetine-induced delusions in psychotic depression. J Clin Psychiatry. 1995;56:7. Letter.
149. Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry. 1993;54:338-342.
150. Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: Should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry. 1992;149: 733-745.
151. McElroy SL, Phillips KA, Keck PE, et al. Body dysmorphic disorder: Does it have a psychotic subtype? J Clin Psychiatry. 1993;54:389-395.
152. Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry. 1994;55(Suppl B):47-52.
153. Flint AJ, Rifat SL. The effect of sequential antidepressant treatment on geriatric depression. J Affect Disord. 1996;36: 95-105.
154. Amsterdam JD, Maislin G, Potter L. Fluoxetine efficacy in treatment resistant depression. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18:243-261.
155. Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA. 1996;275:1897-1902.
156. Weilburg JB, Rosenbaum JF, Biederman J, et al. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: A preliminary report. J Clin Psychiatry. 1989;50:447-449.
157. Zajecka JM, Jeffries H, Fawcett J. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatmentresistant depression: A retrospective analysis. J Clin Psychiatry. 1995;56: 338-343.
158. Horgan D. Combined fluoxetine and desipramine in resistant depression. Aust New Zealand J Psychiatry. 1993;27: 166-168.
159. Phillips KA, Nierenberg AA. The assessment and treatment of refractory depression. J Clin Psychiatry. 1994;55 (Suppl):20-26.
160. Nesse RE, Finlayson RE. Management of depression in patients with coexisting medical illness. Am Fam Phys. 1996;53: 2125-2133.
161. Glassman AH, Bigger JT Jr, Giardina EV, et al. Clinical characteristics of imipramine-induced orthostatic hypotension. Lancet. 1979;1:468-472.
162. Glassman AH, Perel JM. Tricyclic blood levels and clinical outcomes: A review of the art. In: Lipton MA, DiMascio A, Killam KF, eds. Psychopharmacology: A Generation of Progress. New York: Raven Press; 1978:917-922.
163. Stoudemire A. Expanding psychopharmacologic treatment options for the depressed medical patient. Psychosomatics. 1995;36:S19-S26.
164. Shuster JL, Stern TA, Greenberg DB. Pros and cons of fluoxetine for the depressed cancer patient. Oncology. 1992; 6:45-56.
165. Koriech OM. Fluoxetine treatment compromises the antiemetic efficacy of on-dansetron in cancer patients. Clin Oncol. 1995;7:371-372.
166. Razavi D, Allilaire J-F, Smith M, et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. Acta Psychiatr Scand. 1996;94:205-210.
167. Hynes MD, Fuller RW. The effect of fluoxetine on morphine analgesia, respiratory depression, and lethality. Drug Dev Res. 1982;2:33-42.
168. Humphries JE, Whelby MS, VandenBerg SR. Fluoxetine and the bleeding time. Arch Pathol Lab Med. 1990;114: 727-728.
169. Stamenkovic M, Schindler S, Kasper S. Poststroke depression and fluoxetine. Am J Psychiatry. 1996; 153:446-447. Letter.
170. Targ EF, Karasic DH, Diefenbach PN, et al. Structured group therapy and fluoxetine to treat depression in HIV-positive persons. Psychosomatics. 1994;35: 132-137.
171. Rabkin JG, Rabkin R, Wagner G. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. J Clin Psychiatry. 1994;55:92-97.
172. Singh AN, Catalan J. Fluoxetine treatment of major depression in patients with AIDS. Neuropsychopharmacology. 1994; 10:94S. Abstract.
173. Ghaziuddin N, Naylor MW, King CA, Segal HG. Fluoxetine and blood glucose control in adolescents with major depression and insulin-dependent diabetes mellitus. J Child Adolesc Psychopharmacol. 1994;4:87-92.
174. Lonnqvist J, Sihvo S, Syvalahti E, Kiviruusu O. Moclobemide and fluoxetine in atypical depression: A double-blind trial. J Affect Disord. 1994;32:169-177.
175. Stratta P, Bolino F, Cupillari M, Casacchia M. A double-blind, parallel study comparing fluoxetine with imipramine in the treatment of atypical depression. Int Clin Psychopharmacol 1991;6:193-196.
176. Shrand JA, Jellinek MS. Psychopharmacology in mood and anxiety disorders. Contemp Pediatr. 1995;12:21-48.
177. Hazell P, O'Connell D, Heathcote D, et al. Efficacy of tricyclic drugs in treating child and adolescent depression: A metaanalysis. BMJ. 1995;310:897-901.
178. Ghaziuddin N, Naylor MW, King CA. Fluoxetine in tricyclic refractory depression in adolescents. Depression. 1995;2: 287-291.
179. DeVane CL, Sallee FR. Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: A review of published experience. J Clin Psychiatry. 1996;57:55-66.
180. Colle LM, Belair J-F, DiFeo M, et al. Extended open-label fluoxetine treatment of adolescents with major depression. J Child Adolesc Psychopharmacol. 1994; 4:225-232.
181. Simeon JG, Dinicola V, Ferguson HB, Copping W. Adolescent depression: A placebo-controlled fluoxetine treatment study and follow-up. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14: 791-795.
182. Boulos C, Kutcher S, Gardner D, Young E. An open naturalistic trial of fluoxetine in adolescents and young adults with treatment-resistant major depression. J Child Adolesc Psychopharmacol. 1992; 2:103-111.
183. Jain U, Birmaher B, Garcia M, et al. Fluoxetine in children and adolescents with disorders: A chart review of efficacy and adverse effects. J Child Adolesc Psychopharmacol. 1992;2:259-265.
184. Garland EJ, Weiss M. Subgroups of adolescent depression. J Am Acad Child Adolesc Psychiatry. 1995;34:831-833.
185. Dummit ES III, Klein RG, Tancer NK, et al. Fluoxetine treatment of children with selective mutism: An open trial. J Am Acad Child Adolesc Psychiatry. 1996; 35:615-621.
186. Pfeffer CR, Stokes PE, Weiner A, et al. Psychopathology and plasma cortisol responses to dexamethasone in prepubertal psychiatric inpatients. Biol Psychiatry. 1989;26:677-689.
187. Piacentini J, Jaffer M, Gitow A, et al. Psychopharmacologic treatment of child and adolescent obsessive compulsive disorder. Pediatr Psychopharmacol. 1992; 15:87-107.
188. Rasmussen SA, Eisen JL. The epidemiology and clinical features of OCD. Psychiatr Clin North Am. 1992;15:743-758.
189. Riddle MA, Scahill L, King RA, et al. Double-blind crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1992;31:1062-1069.
190. Riddle MA, Hardin MT, King R, et al. Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorder: Preliminary clinical experience. J Am Acad Child Adolesc Psychiatry. 1990;29:45-48.
191. Geller DA, Biederman J, Reed ED, et al. Similarities in response to fluoxetine in the treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1995; 34:36-44.
192. Bouvard M, Dugas M. Fluoxetine in obsessive compulsive disorder in adolescents. Int Clin Psychopharmacol. 1993;8: 307-310.
193. Liebowitz MR, Hollander E, Fairbanks J, Campeas R. Fluoxetine for adolescents with obsessive-compulsive disorder. Am J Psychiatry. 1990;147:370-371. Letter.
194. Bussing R, Levin GM. Methamphetamine and fluoxetine treatment of a child with attention-deficit hyperactivity disorder and obsessive-compulsive disorder. J Child Adolesc Psychopharmacol. 1993;3:53-58.
195. Alessi N, Bos T. Buspirone augmentation of fluoxetine in a depressed child with obsessive-compulsive disorder. Am J Psychiatry. 1991;148:1605-1606. Letter.
196. Graae F, Gitow A, Piacentini J, et al. Response of obsessive-compulsive disorder and trichotillomania to serotonin reuptake blockers. Am J Psychiatry. 1992; 149:149-150. Letter.
197. Cox BJ, Swinson RP, Morrison B, Lee PS. Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive-compulsive disorder: A meta-analysis. J Behav Ther Exp Psychiatry. 1993;24: 149-153.
198. Birmaher B, Waterman GS, Ryan N, et al. Fluoxetine for childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 1994;33:993-999.
199. Black B, Uhde TW. Treatment of elective mutism with fluoxetine: A doubleblind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry.
200. Manassis K, Bradley S. Fluoxetine in anxiety disorders. J Am Acad Child Adolesc Psychiatry. 1994;33:761-762. Letter.
201. Rosenbaum JF, Biederman J, Bolduc EA, et al. Comorbidity of parental anxiety disorders as risk for childhood-onset anxiety in inhibited children. Am J Psychiatry. 1992;149:475-481.
202. Biederman J, Rosenbaum JF, BolducMurphy EA, et al. A 3-year follow-up of children with and without behavioral inhibition. J Am Acad Child Adolesc Psychiatry. 1993;32:814-821.
203. Goldstein DJ, Wilson MG, Thompson VL, and the Fluoxetine Bulimia Nervosa Research Group. Long-term fluoxetine treatment of bulimia nervosa. Br J Psychiatry. 1995;166:660-666.
204. Advokat C, Kutlesic V. Pharmacotherapy of the eating disorders: A commentary. Neurosci Biobehav Rev. 1995;19: 59-66.
205. Levine LR, Pope HG, Enas GG, et al. Fluoxetine in the treatment of bulimia nervosa. Arch Gen Psychiatry. 1992;49: 139-147.
206. Wheadon DE, Wilson MG, Rampey AH, Thompson VL. Fluoxetine in the long-term treatment of bulimia nervosa. Clin Res. 1991;39:769A. Abstract.
207. Wood A. Pharmacotherapy of bulimia nervosa-experience with fluoxetine. Int Clin Psychopharmacol. 1993;8:295-299.
208. Goldbloom DS, Olmsted MP. Pharmacotherapy of bulimia nervosa with fluoxetine: Assessment of clinically significant attitudinal change. Am J Psychiatry. 1993;150:770-774.
209. Bretz WA, Krahn DD, Drury M, et al. Effects of fluoxetine on the oral environment of bulimics. Oral Microbiol Immunol. 1993;8:62-64.
210. Gwirtsman HE, Guze BH, Yager J, Gainsley B. Fluoxetine treatment of anorexia nervosa: An open clinical trial. J Clin Psychiatry. 1990;51:378-382.
211. Kaye WH, Weltzin TE, Hsu LKG, Bulik CM. An open trial of fluoxetine in patients with anorexia nervosa. J Clin Psychiatry. 1991;52:464-471.
212. Brambilla F, Draisci A, Peirone A, Brunetta M. Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 1. Anorexia nervosa-restricted type. Neuropsychobiology. 1995;32:59-63.
213. Brambilla F, Draisci A, Peirone A, Brunetta M. Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders. 2. Anorexia nervosa-binge-eating/purging type. Neuropsychobiology. 1995;32:64-67.
214. Pryor TL, Martin RL, Roach N. Obsessive-compulsive disorder, trichotillomania, and anorexia nervosa: A case report. Int J Eating Disord. 1995;18:375-379.
215. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA. 1996;276:1907-1915.
216. Goldstein DJ, Rampey AH, Roback PJ, et al. Efficacy and safety of long-term fluoxetine treatment of obesity-maximizing success. Obes Res. 1995;3(Suppl 4):481S-490S.
217. Levine LR, Enas GG, Thompson WL, et al. Use of fluoxetine, a selective serotonin uptake inhibitor, in the treatment of obesity: A dose-response study, Int J Obes. 1989;13:635-645.
218. Goldstein DJ, Rampey AH Jr, Enas GG, et al. Fluoxetine: A randomized clinical trial in the treatment of obesity. Int J Obes. 1994;18:129-135.
219. Wise SD. Clinical studies with fluoxetine in obesity. Am J Clin Nutr. 1992; 55:181S-184S.
220. Sayler ME, Goldstein DJ, Roback PJ, Atkinson RL. Evaluating success of weight loss programs, with an application to fluoxetine weight reduction clinical trial data. Int J Obes. 1994;18: 742-751.
221. Goldstein DJ, Rampey AH, Bray GA, Gray D. Fluoxetine treatment of obese patients with noninsulin dependent diabetes mellitus. Clin Res. 1991;39:767A. Abstract.
222. Connolly VM, Gallagher A, Kesson CM. A study of fluoxetine in obese elderly patients with type 2 diabetes. Diabetic Med. 1995;12:416-418.
223. Regier DA, Farmer ME, Rae DS, et al. One-month prevalence of mental disorders in the United States and sociodemographic characteristics: The Epidemiologic Catchment Area Study. Acta Psychiatr Scand. 1993;88:35-47.
224. Robins LN, Heizer JE, Weissman MM, et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry. 1984;41:949-958.
225. Goodman WK, McDougle CJ, Price LH. Pharmacotherapy of obsessive-compulsive disorder. J Clin Psychiatry. 1992;35 (Suppl 4):29-37.
226. Perse T. Obsessive-compulsive disorder: A treatment review. J Clin Psychiatry. 1988;49:48-55.
227. Piccinelli M, Pini S, Bellantuono C, Wilkinson G. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry. 1995;166:424-443.
228. Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry. 1995;52:53-60.
229. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. Part 1. Development, use and reliability. Arch Gen Psychiatry. 1989;46:1006-1011.
230. Wheadon DE, Bushnell WD, Steiner M. A fixed dose comparison of 20, 40, or 60 mg paroxetine to placebo in the treatment of obsessive-compulsive disorder. Poster presented at the American College of Neuropharmacology Meeting; December 1993; Puerto Rico.
231. López-Ibor JJ Jr, Saiz J, Cottreaux J, et al. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur Neuropsychopharmacol. 1996;6:111-118.
232. Pigott TA, Pato MT, Bernstein SE, et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1990;47:926-932.
233. Saiz Ruiz J, López-Ibor JJ Jr, Cottreaux J, et al. Double-blind comparison of fluoxetine and clomipramine in obsessive-compulsive disorder. Eur Neuropsychopharmacol. 1992;2:204-205. Abstract.
234. Pato MT, Zohar J. Current Treatments of Obsessive-Compulsive Disorder. Washington, DC: American Psychiatric Press; 1991:13-28.
235. Pato MT, Zohar-Kadouch R, Zohar J, Murphy DL. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry. 1988;145: 1521-1525.
236. Ravizza L, Barzega G, Bellino S, et al. Drug treatment of obsessive-compulsive disorder (OCD): Long-term trial with clomipramine and selective serotonin re-uptake inhibitors (SSRIs). Psychopharmacol Bull. 1996;32:167-173.
237. Laird LK. Issues in the monotherapy and polypharmacotherapy of obsessive-compulsive disorder. Psychopharmacol Bull. 1996;32:569-578.
238. lancu I, Weizman A, Kindler S, et al. Serotonergic drugs in trichotillomania: Treatment results in 12 patients. J Nerv Ment Dis. 1996;184:641-644. Brief report.
239. Christenson GA, Crow SJ. The characterization and treatment of trichotillomania. J Clin Psychiatry. 1996;57(Suppl 8):42-49.
240. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. NEJM. 1995;332: 1529-1534.
241. Wood SH, Mortola JF, Chan Y-F, et al. Treatment of premenstrual syndrome with fluoxetine: A double-blind, placebocontrolled, crossover study. Obstet Gynecol. 1992;80:339-344.
242. Menkes DB, Taghavi E, Mason PA, Howard RC. Fluoxetine's spectrum of action in premenstrual syndrome. Int Clin Psychopharmacol. 1993;8:95-102.
243. Pearlstein TB, Stone AB. Long-term fluoxetine treatment of late luteal phase dysphoric disorder. J Clin Psychiatry. 1994; 55:332-335.
244. Nierenberg AA, McLean NE, Alpert JE, et al. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry. 1995;152:1500-1503.
245. Quitkin FM, Rabkin JG, Markowitz JM, et al. Use of pattern analysis to identify true drug response: A replication. Arch Gen Psychiatry. 1987;44:259-264.
246. Pope HG Jr, McElroy SL, Nixon RA. Possible synergism between fluoxetine and lithium in refractory depression. Am J Psychiatry. 1988;145:1292-1294.
247. Ontiveros A, Fontaine R, Elie R. Refractory depression: The addition of lithium to fluoxetine or desipramine. Acta Psychiatr Scand. 1991;83:188-192.
248. Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: A double-blind, placebo-controlled study. Am J Psychiatry. 1994;151: 1372-1374.
249. Katona CL, Abou-Saleh MT, Harrison DA, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry. 1995;166: 80-86.
250. Hawley CJ, Roberts AG, Baldwin DS. Tolerability of combined treatment with lithium and fluoxetine: 14 Cases treated under open conditions. Int Clin Psychopharmacol. 1994;9:31-33.
251. Bauer M, Linden M, Schaaf B, Weber HJ. Adverse events and tolerability of the combination of fluoxetine/lithium compared with fluoxetine. J Clin Psychopharmacol. 1996;16:130-134.
252. Breuel HP, Muller-Oerlinghausen B, Nickelsen T, Heine PR. Pharmacokinetic interactions between lithium and fluoxetine after single and repeated fluoxetine administration in young healthy volunteers. Int J Clin Pharmacol Ther 1995; 33:415-419.
253. Muly EC, McDonald W, Steffens D, Book S. Serotonin syndrome produced by a combination of fluoxetine and lithium. Am J Psychiatry. 1993;150:1565. Letter.
254. Flint AJ, Rifat SL. A prospective study of lithium augmentation in antidepressant-resistant geriatric depression. J Clin Psychopharmacol. 1994;14:353-356.
255. Pérez V, Gilaberte I, Fanes D, et al. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 1997;349:1594-1597.
256. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol. 1996;15:217-221.
257. Moreno FA, Delgado PL, Bachar K, Gelenberg AJ. Pindolol augmentation in treatment-resistant depressed patients. Psychopharmacol Bull. 1996;32:492. Abstract.
258. Berman RM, Darnell AM, Miller HL, et al. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: A double-blind, placebo-controlled trial. Am J Psychiatry. 1997;154:37-43.
259. El-Yazigi A, Chaleby K, Gad A, Raines DA. Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. J Clin Pharmacol. 1995; 35:17-21.
260. Nelson JG, Mazure CM, Bowers MB, et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991;48:303-307.
261. Tiffon L, Coplan JD, Papp LA, Gorman JM. Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. J Clin Psychiatry. 1994;55:66-69.
262. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry. 1991;52:217-220.
263. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin re-uptake inhibitors in refractory depression. J Clin Psychiatry. 1993;54: 269-271.
264. Markovitz PJ, Stagno SJ, Calabrese JR. Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry. 1990;147:798-800.
265. Jenike MA, Bair L, Buttolph L. Buspirone augmentation of fluoxetine in patients with obsessive-compulsive disorder. J Clin Psychiatry. 1991:52:13-14.
266. Grady TA, Pigott TA, L'Heureux F, et al. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry. 1993;150:819-821.
267. Leonard HL, Topol D, Bukstein O, et al. Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1994;33: 792-794.
268. Smith WT, Longborg PD, Glaudin V, Painter JR. Clonazepam augmentation of fluoxetine in the treatment of outpatients with major depression: A double-blind, placebo-controlled, multicenter study. Psychopharmacol Bull. 1996;32:519. Abstract.
269. Stoll AL, Pillay SS, Diamond L, et al. Methylphenidate augmentation of serotonin selective reuptake inhibitors: A case series. J Clin Psychiatry. 1996;57:72-76.
270. Barak Y, Stein D, Levine J, et al. Thyroxine augmentation of fluoxetine treatment for resistant depression in the elderly: An open trial. Hum Psychopharmacol. 1996;11:463-467.
271. Stokes PE. The potential role of excessive cortisol induced by HPA hyperfunction in the pathogenesis of depression. Eur Neuropsychopharmacol. 1995;Suppl: 77-82.
272. Dinan TG, Lavelle E, Cooney J, et al. Dexamethasone augmentation in treatment-resistant depression. Acta Psychiatr Scand. 1997;95:58-61.
273. Stokes PE. A primary care perspective on management of acute and long-term depression. J Clin Psychiatry. 1996;54 (Suppl):74-84.
274. Montgomery SA. Efficacy in long-term treatment of depression. J Clin Psychiatry. 1996;57(Suppl 2):24-30.
275. Tollefson GD. Adverse drug reactions/ interactions in maintenance therapy. J Clin Psychiatry. 1993;54(Suppl):48-58.
276. Montgomery SA. Long-term treatment of depression. Br J Psychiatry. 1994; 165(Suppl 26):31-36.
277. Fava M, Rappe SM, Pava JA, et al. Relapse in patients on long-term fluoxetine treatment: Response to increased fluoxetine dose. J Clin Psychiatry. 1995;56: 52-55.
278. Frenkel A, Rosenthal J, Nezu A, Winston A. Efficacy of long-term fluoxetine treatment of obsessive-compulsive disorder. Mt Sinai J Med. 1990;57:348-352.
279. Levine R, Huffman JS, Knepple ED, Kenin M. Long-term fluoxetine treatment of a large number of obsessive-compulsive patients. J Clin Psychopharmacol. 1989;9:281-283.
280. Fava GA, Grandi S. Withdrawal syndromes after paroxetine and sertraline discontinuation. J Clin Psychopharmacol. 1995;15:374-375.
281. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol. 1996:16:356-362.
282. Prozac®. In: Physicians'Desk Reference®. 51 st ed. Montvale, NJ: Medical Economics Company, Inc; 1997:935-940.
283. Beasley CM, Potvin JH. Fluoxetine: Activating and sedating effects, Int Clin Psychopharmacol. 1993;8:271-275.
284. Amsterdam JD, Hornig-Rohan M, Maislin G. Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression. J Clin Psychiatry. 1994;55:394-400.
285. Shen WW, Hsu JH. Female sexual side effects associated with selective serotonin reuptake inhibitors: A descriptive clinical study of 33 patients. Int J Psychiatry Med. 1995;25:239-248.
286. Hsu JH, Shen WW. Male sexual side effects associated with antidepressants: A descriptive clinical study of 32 patients. Int J Psychiatry Med. 1995;25:191-201.
287. Patterson WM. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry. 1993; 54:2. Letter.
288. Zajecka J, Fawcett J, Schaff M, et al. The role of serotonin in sexual dysfunction: Fluoxetine-associated orgasm dysfunction. J Clin Psychiatry. 1991;52:66-68.
289. Modell JG, Katholi CR, Modell JD, De-Palma RL. Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther. 1997;61:476-487.
290. Jacobsen FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry. 1992;53: 119-122.
291. Benazzi F, Mazzoli M. Fluoxetine-induced sexual dysfunction: A dose-dependent effect? Pharmacopsychiatry. 1994;27:246.
292. Lane RM. A critical review of selective serotonin reuptake inhibitor-related sexual dysfunction; incidence, possible aetiology and implications for management. J Psychopharmacol. 1997;11:72-82.
293. Balogh S, Hendricks SE, Kang J. Treatment of fluoxetine-induced anorgasmia with amantadine. J Clin Psychiatry. 1992;53:212-213.
294. Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry. 1993;54: 459-465.
295. Cohen AJ. Fluoxetine-induced yawning and anorgasmia reversed by cyproheptadine treatment. J Clin Psychiatry. 1992; 53:174. Letter.
296. Aizenberg D, Zemishlany Z, Weizman A. Cyproheptadine treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin Neuropharmacol. 1995;18:320-324.
297. Shrivastava RK, Shrivastava S, Overweg N, Schmitt M. Amantadine in the treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 1995; 15:83-84. Letter.
298. Hollander E, McCarley A. Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers. J Clin Psychiatry 1992;53:207-209.
299. Norden MJ. Buspirone treatment of sexual dysfunction associated with selective serotonin re-uptake inhibitors. Depression. 1994;2:109-112. Case studies.
300. Bartlik BD, Kaplan P, Kaplan HS. Psychostimulants apparently reverse sexual dysfunction secondary to selective serotonin re-uptake inhibitors. J Sex Marital Ther. 1995;21:264-271.
301. Lineberry CG, Johnston JA, Raymond RN, et al. A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. J Clin Psychiatry. 1990;51:194-199.
302. Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dysfunction: Efficacy of a drug holiday. Am J Psychiatry. 1995;152:1514-1516.
303. Tollefson GD. Antidepressant treatment and side effect consideration. J Clin Psychiatry. 1991;52(Suppl):4-13.
304. Kulig K. Management of poisoning associated with "newer" antidepressant agents. Ann Emerg Med. 1986;15:1039/ 81-1045/87.
305. Montgomery SA. The benefits and risks of 5-HT uptake inhibitors in depression. Br J Psychiatry. 1988;153(Suppl 3):7-10.
306. Finley PR. Selective serotonin reuptake inhibitors: Pharmacologic profiles and potential therapeutic distinctions. Ann Pharmacother. 1994;28:1359-1369.
307. DeVane CL. Comparative safety and tolerability of selective serotonin reuptake inhibitors. Hum Psychopharmacol. 1995; 10:S185-S193.
308. Kasper S, Heiden A. Do SSRIs differ in their antidepressant efficacy? Hum Psychopharmacol. 1995;10:S163-S172.
309. Fisher S, Kent TA, Bryant SG. Postmarketing surveillance by patient self-monitoring: Preliminary data for sertraline versus fluoxetine. J Clin Psychiatry. 1995;56:288-296.
310. Delini-Stula A, Mikkelsen H, Angst J. Side-effects and drug-interaction profiles of moclobemide (RIMA) and fluoxetine. Pharmacopsychiatry. 1995;28: 171. Abstract.
311. Montgomery SA. Safety of mirtazapine: A review, Int Clin Psychopharmacol. 1995;10(Suppl 4):37-45.
312. Serzone®. In: Physicians' Desk Reference®. 51st ed. Montvale, NJ: Medical Economics Company, Inc; 1997:776-779.
313. Pai VB, Kelly MW. Bruising associated with the use of fluoxetine. Ann Pharmacother. 1996;30:786-788.
314. Gunzberger DW, Martinez D. Adverse vascular effects associated with fluoxetine. Am J Psychiatry. 1992;149:1751. Letter.
315. Wilmshurst PT, Kumar AV. Subhyaloid hemorrhage with fluoxetine. Eye. 1996; 10:141. Letter.
316. Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ. Fluoxetine and bleeding in obsessive-compulsive disorder. Am J Psychiatry. 1991:148:949. Letter.
317. Aranth J, Lindberg C. Bleeding, a side effect of fluoxetine. Am J Psychiatry. 1992;149:412. Letter.
318. Humphries JE, Wheby MS, VandenBerg SR. Fluoxetine and the bleeding time. Arch Pathol Lab Med. 1990;114: 727-728. Case report.
319. Berk M, Jacobsen BF, Hurly E. Fluoxetine and hemostatic function: A pilot study. J Clin Psychiatry. 1995;56:14-16.
320. Alderman CP, Seshadri P, Ben-Tovim DI. Effects of serotonin reuptake inhibitors on hemostasis. Ann Pharmacother. 1996; 30:1232-1234.
321. Woolfrey S, Gammack NS, Dewer MS, Brown PJE. Fluoxetine-warfarin interaction. BMJ. 1993;307:241.
322. Dent LA, Orrock MW. Warfarin-fluoxetine and diazepam-fluoxetine interaction. Pharmacotherapy. 1997;17:170-172.
323. Buckley NA, Dawson AH. Drug interactions with warfarin. Med J Aust. 1992; 157:479-483.
324. Berkow R, Fletcher AJ, eds. The Merck Manual of Diagnosis and Therapy. 16th ed. Rahway, NJ: Merck Research Laboratories; 1992:520.
325. Rowe H, Carmichael R, Lemberger L. The effect of fluoxetine on warfarin metabolism in the rat and man. Life Sci. 1978;23:807-811.
326. Siegler EL, Tamers D, Berlin JA, et al. Risk factors for the development of hyponatremia in psychiatric inpatients. Arch Intern Med. 1995;155:953-957.
327. Pillans PI, Coulter DM. Fluoxetine and hyponatraemia - a potential hazard in the elderly. New Zealand Med J. 1994;107: 85-86.
328. Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: A review of spontaneous reports. Can Med Assoc J. 1996;155:519-527.
329. Arya DK. Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br J Psychiatry. 1994;165: 728-733.
330. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry. 1996;57: 449-454.
331. Coulter DM, Pillans PI. Fluoxetine and extrapyramidal side effects. Am J Psychiatry. 1995;152:122-123.
332. Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry. 1992;53:278-282.
333. Lipinski JF, Mallya G, Zimmerman P, Pope HG. Fluoxetine induced akathisia: Clinical and theoretical implications. J Clin Psychiatry. 1989;50:339-342.
334. Lejoyeux M, Ades J, Mourad I, et al. Antidepressant withdrawal syndrome. Recognition, prevention and management. Drug Ther. 1996;5:278-292.
335. Price JS, Waller PC, Wood SM, et al. A comparison of the post-marketing safety of tour selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol. 1996;42:757-763.
336. Lazowick AL, Levin GM. Potential withdrawal syndrome associated with SSRI discontinuation. Ann Pharmacother. 1995;29:1284-1285.
337. Committee of Safety of Medicines. Dystonia and withdrawal symptoms with paroxetine. Curr Probl Pharmacovigil. 1993;19:1.
338. Barr LC, Goodman WK, Price LH. Physical symptoms associated with paroxetine discontinuation. Am J Psychiatry. 1994;151:289. Letter.
339. Keuthen N. Cyr P, Ricciardi AJ, et al. Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. J Clin Psychopharmacol. 1994;14:206-207.
340. Frost L, Lai S. Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors. Am J Psychiatry. 1995;152:810. Letter.
341. Hartmann L. Physical symptoms associated with paroxetine withdrawal. Am J Psychiatry. 1995;152:1235-1236.
342. Bloch M, Stager SV, Braun AR, Rubinow DR. Severe psychiatric symptoms associated with paroxetine withdrawal. Lancet. 1995:346:57. Letter.
343. Koopowitz. LF, Berk M. Paroxetine induced withdrawal effects. Hum Psychopharmacol. 1995;10:147-148.
344. Phillips S. A possible paroxetine withdrawal syndrome. Am J Psychiatry. 1995; 152:645-646. Letter.
345. Pyke R. Paroxetine withdrawal syndrome. Am J Psychiatry. 1995;152: 149-150. Letter.
346. Bhaumik S, Collacott RA, Gandhi D, et al. A naturalistic study in the use of antidepressants in adults with learning disabilities and affective disorders. Hum Psychopharmacol. 1995;10:283-288.
347. Bhaumik S. Wildgust HJ. Treatment outcomes including withdrawal phenomena with fluoxetine and paroxetine in patients with learning disabilities suffering from affective disorders. Hum Psychopharmacol. 1996;11:337-338. Letter.
348. Mallya G, White K, Gunderson C. Is there a serotoninergic withdrawal syndrome? Biol Psychiatry. 1993;33:851-852.
349. Otani K, Tanaka O, Kaneko S, et al. Mechanisms of the development of trazodone withdrawal symptoms. Int Clin Psychopharmacol. 1994;9:131-133.
350. Stoukides JA, Stoukides CA. Extrapyramidal symptoms upon discontinuation of fluoxetine. Am J Psychiatry. 1991;148: 1263. Letter.
351. Kasantikul D. Reversible delirium after discontinuation of fluoxetine. J Med Assoc Thailand. 1995;78:53-54.
352. Einbinder E. Fluoxetine withdrawal? Am J Psychiatry. 1995;152:1235. Letter.
353. Cohen LS, Altshuler LL. Pharmacologic management of psychiatric illness during pregnancy and the postpartum period. Psychiatr Clin North Am. 1997;4:21-60.
354. Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: Dilemmas and guidelines. Am J Psychiatry. 1996; 153:592-606.
355. Nulman I, Koren G. The safety of fluoxetine during pregnancy and lactation. Teratology. 1996;53:304-308.
356. Byrd RA, Brophy GT, Markham JK. Developmental toxicology studies of fluoxetine hydrochloride (I) administered orally to rats and rabbits. Teratology. 1989;39:444. Abstract P67.
357. Stanford MS, Patton JH. In utero exposure to fluoxetine HCI increases hematoma frequency at birth. Pharmacol Biochem Behav. 1995;45:959-962.
358. Horng JS, Wong DT. Effects of serotonin uptake inhibitor, Lilly 110140, on transport of serotonin in rat and human blood platelets. Biochem Pharmacol. 1976;25: 865-867.
359. Hoyt JA, Byrd RA, Brophy GT, Markham JK. A reproduction study of fluoxetine hydrochloride (I) administered in the diet to rats. Teratology. 1989;39: 459. Abstract P68.
360. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac) [see comments]. JAMA. 1993; 269:2246-2248.
361. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine [see comments]. NEJM. 1996;335:1010-1015.
362. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. NEJM. 1997;336:258-262.
363. Marden PM, Smith DW, McDonald MJ. Congenital anomalies in the newborn infant, including minor variations: A study of 4,412 babies by surface examination for anomalies and buccal smear for sex chromatin. J Pediatr. 1964;64:357-371.
364. Leppig KA, Werler MM, Cann CI, et al. Predictive value of minor anomalies. I. Association with major malformations. J Pediatr. 1987;110:531-537.
365. Goldstein DJ. Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol. 1995;15:417-420.
366. Cohler BJ, Gallant DH, Grunebaum HU, et al. Pregnancy and birth complications among mentally ill and well mothers and their children. Soc Biol. 1976;22:269-278.
367. Briggs GG, Freeman RK, Yaffee SJ. Drugs in Pregnancy and Lactation. 4th ed. Baltimore, Md: Williams & Wilkins; 1994:374-375.
368. Kuller JA, Katz VL, McMahon MJ, et al. Pharmacologic treatment of psychiatric disease in pregnancy and lactation: Fetal and neonatal effects. Obstet Gynecol. 1996;87:789-794.
369. Cooper GL. The safety of fluoxetine: An update. Br J Psychiatry. 1988;155:77-86.
370. Koren G. First-trimester exposure to fluoxetine (Prozac). Does it affect pregnancy outcome? Can Fam Phys. 1996; 42:43-44.
371. Shader RI. Does continuous use of fluoxetine during the first trimester of pregnancy present a high risk for malformation or abnormal development to the exposed fetus? J Clin Psychopharmacol. 1992;12:441.
372. Taddio A, Ito S, Koren G. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk. J Clin Pharmacol. 1996;36:42-47.
373. Duffull SB, Begg EJ, Ilett KF. Fluoxetine distribution in human milk. J Clin Pharmacol. 1996;36:1078. Letter.
374. Lester BM, Cucca J, Andreozzi L, et al. Possible association between fluoxetine hydrochloride and colic in an infant. J Am Acad Child Adolesc Psychiatry. 1993; 32:1253-1255.
375. Burch KJ, Wells BG. Fluoxetine/norfluoxetine concentrations in human milk. Pediatrics. 1992;89:676-677.
376. Isenberg KE. Excretion of fluoxetine in human breast milk. J Clin Psychiatry. 1990;51:169. Letter.
377. Wisner KL, Perel JM, Findling RL. Antidepressant treatment during breastfeeding. Am J Psychiatry. 1996;153: 1132-1137.
378. Gjerdingen DK, Chaloner KM. The relationship of women's postpartum mental health to employment, childbirth, and social support. J Fam Pract. 1994;38: 465-472.
379. Green M. Maternal depression: Bad for children's health. Contemp Pediatr. 1993; 10:28-36.
380. Neugebauer R, Kline J, Shrout P, et al. Major depressive disorder in the 6 months after miscarriage. JAMA. 1997; 277:383-388.
381. de Jonghe F, Swinkels JA. The safety of antidepressants. Drugs. 1992;43(Suppl 2):40-47.
382. Feierabend RH. Benign course in a child with a massive fluoxetine overdose. J Fam Pract. 1995;41:289-291.
383. Wernicke JF. The side effect profile and safety of fluoxetine. J Clin Psychiatry. 1985;46:59-67.
384. Rohrig TP, Prouty RW. Fluoxetine overdose: A case report. J Anal Toxicol. 1989;13:305-307.
385. Kincaid RL, McMullin MM, Crookham SB, Rieders F. Report of a fluoxetine fatality. J Anal Toxicol. 1990;14:327-329.
386. Prozac®. Physicians' Desk Reference®. 48th ed. Montvale, NJ: Medical Economics Data; 1994:880.
387. Borys DJ, Setzer SC, Ling LJ, et al. Acute fluoxetine overdose: A report of 234 cases. Am J Emerg Med. 1992;10:115-120.
388. Braitberg G, Curry SC. Seizure after isolated fluoxetine overdose. Ann Emerg Med. 1995;26:234-237.
389. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. BMJ. 1995;310:221-224.
390. Tollefson GD, Rampey AH, Beasley CM, et al. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. J Clin Psychopharmacol. 1994;14:163-169.
391. Guze SB, Robins E. Suicide and primary affective disorders. Br J Psychiatry. 1970;117:437-438.
392. Pallis DJ, Sainsbury P. Seriousness of suicide attempt in relation to personality. Br J Psychiatry. 1977;130:253-259.
393. Brent DA, Kupfer DJ, Bromet EJ, et al. The assessment and treatment of patients at risk for suicide. In: Frances AJ, Hales RE, eds. Review of Psychiatry. Washington, DC: American Psychiatric Press; 1988;7:353-385.
394. Murphy B, Kelleher MJ. Does fluoxetine induce suicidal thoughts? Ir J Psychol Med. 1994;11:99-100.
395. Hagnell O, Lanke J, Rorsman B. Suicide rates in the Lundby study: Mental illness as a risk factor for suicide. Neuropsychobiology. 1981;7:248-253.
396. Roose SP, Classman AH. Delusional depression. In: Georgotas A, Cancro R, eds. Depression and Mania. New York, NY: Elsevier; 1988:76-85.
397. Serotonin, suicidal behaviour and impulsivity. Lancet. 1987;2:949-950. Editorial.
398. King RA, Segman RH, Anderson GM. Serotonin and suicidality: The impact of acute fluoxetine administration. I: Serotonin and suicide. Isr J Psychiatry Relat Sci. 1994;31:271-279.
399. Montgomery SA, Montgomery DB, Green M, et al. Pharmacotherapy in the prevention of suicidal behavior. J Clin Psychopharmacol. 1992;12(Suppl 2): 27S-31S.
400. Mann JJ, Kapur S. The emergence of suicidal ideation and behavior during antidepressant pharmacotherapy. Arch Gen Psychiatry. 1991;48:1027-1033.
401. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry. 1990;147:207-210.
402. King RA, Riddle MA, Chappell PB, et al. Emergence of self destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry. 1991;30: 179-186.
403. King RA, Anderson GM, Rasmusson AM, Riddle MA. Fluoxetine mechanism of action. J Am Acad Child Adolesc Psychiatry. 1991;30:849-850. Letter.
404. Power AC, Cowen PJ. Fluoxetine and suicidal behavior. Some clinical and theoretical aspects of a controversy. Br J Psychiatry. 1992;161:735-741.
405. Beasley CM, Dornseif BE, Bosomworth JC, et al. Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression. Int Clin Psychopharmacol. 1992;6(Suppl 6):35-57.
406. Rothschild AJ, Locke CA. Re-exposure to fluoxetine after serious suicide attempts by three patients: The role of akathisia. J Clin Psychiatry. 1991;52: 491-493.
407. Dasgupta K. Additional cases of suicidal ideation associated with fluoxetine. Am J Psychiatry. 1990;147:1570. Letter.
408. Tollefson GD, Fawcett J, Winokur G, et al. Evaluation of suicidality during pharmacologic treatment of mood and non-mood disorders. Ann Clin Psychiatry. 1993;5:209-224.
409. Goldstein DJ, Rampey AH, Potvin JH, et al. Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction. J Clin Psychiatry. 1993;54:309-316.
410. Warshaw MG, Keller MB. The relationship between fluoxetine use and suicidal behavior in 654 subjects with anxiety disorders. J Clin Psychiatry. 1996;57: 158-166.
411. Mann JJ, Goodwin FK, O'Brien C, et al. Suicidal behavior and psychotropic medication. Consensus statement by the ACNP Council, March 2, 1992. Neuropsychopharmacology. 1993;8:177-182.
412. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study. JAMA. 1990;264:2511-2518.
413. Lee HS, Song DH, Rhee HS, et al. An open trial of fluoxetine in the treatment of premature ejaculation. Neuropsychopharmacology. 1994;10(3, Suppl, Pt 2):160S. Poster.
414. Kara H, Aydin S, Agargün MY, et al. The efficacy of fluoxetine in the treatment of premature ejaculation: A double-blind placebo controlled study. J Urol. 1996; 156:1631-1632.
415. Fuller RW. The influence of fluoxetine on aggressive behavior. Neuropsychopharmacology. 1996;14:77-81.
416. Heiligenstein JH, Coccaro EF, Potvin JH, et al. Fluoxetine not associated with increased violence or aggression in controlled clinical trials. Ann Clin Psychiatry. 1992;4:383-395.
417. Fava M, Rosenbaum JF, Pava JA, et al. Anger attacks in unipolar depression, part 1: Clinical correlates and response to fluoxetine treatment. Am J Psychiatry. 1993; 150:1158-1163.
418. Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol. 1995;15:23-29.
419. Cornelius JR, Salloum IM, Cornelius MD, et al. Fluoxetine trial in
420. Roy A, Linnoila M. Alcoholism and suicide. Suicide Life-Threat Behav. 1986;16: 244-273.
421. Angst J, Bastrup P, Grof P, et al. The course of monopolar depression and bipolar psychosis. Psychiatr Neurol Neurochir. 1973;76:489-500.
422. Ballenger JC, Goodwin FK, Major LF, et al. Alcohol and central serotonin metabolism in man. Arch Gen Psychiatry. 1979; 36:224-227.
423. Banki CM. Factors influencing monoamine metabolites and tryptophan in patients with alcohol dependence. J Neural Transm. 1981;50:89-101.
424. Banki CM, Arato M, Papp Z, et al. Biochemical markers in suicidal patients. J Affect Disord. 1984;6:341-350.
425. Murphy JM, McBride WJ, Lumeng L, et al. Regional brain levels of monoamines in alcohol-preferring and nonpreferring lines of rats. Pharmacol Biochem Behav. 1982;16:145-149.
426. 2 and β-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry. 1986;43:954-959.
427. Cornelius JR, Salloum IM, Cornelius MD, et al. Alcohol dependence. Preliminary report: Double-blind, placebo-controlled study of fluoxetine in depressed alcoholics. Psychopharmacol Bull. 1995; 31:297-303.
428. Janiri L, Gobbi G, Mannelli P, et al. Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. Int Clin Psychopharmacol. 1996; 11:109-117.
429. Gerra G, Caccavari R, Delsignore R, et al. Effects of fluoxetine and Ca-acetylhomotaurinate on alcohol intake in familial and nonfamilial alcoholic patients. Curr Ther Res. 1992;52:291-295.
430. Shaw CA, Sullivan JT, Kadlec KE, et al. Ethanol interactions with serotonin uptake selective and nonselective antidepressants: Fluoxetine and amitriptyline. Hum Psychopharmacol. 1989;4:113-120.
431. Hardens M. Differential costs of treatment of depression with SSRIs. Hum Psychopharmacol. 1995;10:S195-S197.
432. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry. 1993;54:405-418.
433. Franco K, Tamburino M, Campbell N, et al. The added costs of depression to medical care. PharmacoEconomics. 1995;7: 284-291.
434. Katon W, Kleinman A, Rosen G. Depression and somatization: A review. Part I. Am J Med. 1982;72:127-135.
435. Katon W, Kleinman A, Rosen G. Depression and somatization: A review. Part II. Am J Med. 1982;72:241-247.
436. Eisenberg L. Treating depression and anxiety in primary care: Closing the gap between knowledge and practice. NEJM. 1992;326:1080-1084.
437. Von Korff M, Ormel J, Katon W, Lin EHB. Disability and depression among high utilizers of health care. A longitudinal analysis. Arch Gen Psychiatry. 1992; 49:91-100.
438. Wells KB, Hays RD, Brunam A, et al. Detection of depressive disorder for patients receiving prepaid or fee-for-service care. JAMA. 1989;262:3298-3302.
439. Gerber PD, Barrett J, Barrett J, et al. Recognition of depression by internists in primary care: A comparison of internist and "gold standard" psychiatric assessment. J Gen Intern Med. 1989;4:7-13.
440. Shapiro S, German PS, Skinner A, et al. An experiment to change detection and management of mental morbidity in primary care. Med Care. 1987;25:327-329.
441. Block M, Schulberg HC, Coulehan JC, et al. Diagnosing depression among new patients in ambulatory training settings. J Am Board Fam Pract. 1988;1:91-97.
442. Simon GE, Von Korff M. Recognition, management, and outcomes of depression in primary care. Arch Fam Med. 1995;4:99-105.
443. Covinsky KE, Fortinsky RH, Palmer RM, et al. Relation between symptoms of depression and health status outcomes in acutely ill hospitalized older persons. Ann Intern Med. 1997;126:417-425.
444. Callahan CM, Kesterson JG, Tierney WM. Association of symptoms of depression with diagnostic test charges among older adults. Ann Intern Med. 1997;126: 426-432.
445. Judd LL, Rapaport MH. Economics of depression and cost-benefit comparisons of selective serotonin reuptake inhibitors and tricyclic antidepressants. Depression. 1995; 2:173-177.
446. DeVane CL. Pharmacokinetics of the newer antidepressants: Clinical relevance. Am J Med. 1994;97(Suppl 6A): 13-23.
447. Kilts CD. Recent pharmacologic advances in antidepressant therapy. Am J Med. 1994;97(Suppl 6A):3-12.
448. Lane R, McDonald G. Reducing the economic burden of depression. Int Clin Psychopharmacol. 1994;9:229-243.
449. McCombs JS, Nichol MB, Stimmel GL, et al. The cost of antidepressant drug therapy failure: A study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry. 1990;51:60-69.
450. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: Economic outcomes in a health maintenance organization. Clin Ther. 1994;16:715-730.
451. Thompson D, Buesching D, Gregor KJ, Oster G. Patterns of antidepressant use and their relation to costs of care. Am J Managed Care. 1996;2:1239-1246.
452. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: Economic evaluation of fluoxetine, paroxetine, and sertraline in a health maintenance organization. J Int Med Res. 1995; 23:395-412.
453. Simpson HB, Nee JC, Endicott J. Firstepisode major depression: Few sex differences in course. Arch Gen Psychiatry. 1997;54:633-639.